Neuralstem (CUR) Getting Somewhat Positive Press Coverage, Study Finds

News coverage about Neuralstem (NASDAQ:CUR) has trended somewhat positive on Wednesday, according to Accern Sentiment. The research group ranks the sentiment of news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Neuralstem earned a media sentiment score of 0.10 on Accern’s scale. Accern also gave press coverage about the company an impact score of 46.718759386539 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

Neuralstem (NASDAQ:CUR) last announced its quarterly earnings results on Tuesday, August 8th. The company reported ($0.39) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($9.49) by $9.10. Neuralstem had a negative net margin of 198,573.91% and a negative return on equity of 321.78%.

Separately, ValuEngine cut shares of Neuralstem from a “hold” rating to a “sell” rating in a research note on Tuesday, July 25th.

WARNING: “Neuralstem (CUR) Getting Somewhat Positive Press Coverage, Study Finds” was published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this article on another website, it was illegally stolen and reposted in violation of US & international copyright law. The legal version of this article can be viewed at https://sportsperspectives.com/2017/11/01/neuralstem-cur-getting-somewhat-positive-press-coverage-study-finds.html.

About Neuralstem

Neuralstem, Inc (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform.

Insider Buying and Selling by Quarter for Neuralstem (NASDAQ:CUR)

Receive News & Ratings for Neuralstem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuralstem Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply